Skip to main content

Table 3 Seropositivity rates and GMTs for anti-CS and Anti-HBs antibodies (ATP cohort for immunogenicity)

From: Evaluation of two formulations of adjuvanted RTS, S malaria vaccine in children aged 3 to 5 years living in a malaria-endemic region of Mozambique: a Phase I/IIb randomized double-blind bridging trial

Group

Timing

N

Seropositives

   

MIN

MAX

     

95% CI

GMT

95% CI

  
   

n

%

LL

UL

 

LL

UL

  

GMTs anti-CS antibodies (EU/mL)

RTS, S/AS02D

Pre

67

9

13,4

6,3

24

0,3

0,3

0,4

< 0,5

8

 

PIII(M3)

67

67

100

94,6

100

191

150

242

14

1314

 

PIII(M14)

60

60

100

94

100

22

15

32

0,5

543

RTS, S/AS02A

Pre

76

10

13,2

6,5

22,9

0,3

0,3

0,4

< 0,5

8

 

PIII(M3)

76

76

100

95,3

100

180

146

221

16

1277

 

PIII(M14)

67

67

100

94,6

100

29

22

39

1

323

GMTs anti-HBs antibodies (mIU/mL)

RTS, S/AS02D

Pre

67

6

9,0

3,4

18,5

8

5

11

< 10

2211

 

PIII(M3)

67

67

100

94,6

100

23978

17896

32127

985

446880

 

PIII(M14)

60

60

100

94,0

100

5184

4043

6646

653

100110

RTS, S/AS02A

Pre

76

5

6,6

2,2

14,7

6

5

8

< 10

1759

 

PIII(M3)

76

76

100

95,3

100

17410

13322

22752

1265

823500

 

PIII(M14)

66

66

100

94,6

100

5024

3918

6443

877

260700

  1. N: number of subjects with available results; GMT: geometric mean antibody titer calculated on all subjects; MIN/MAX: Minimum/Maximum; n (%): number (percentage) of subjects with titer ≥ 0.5 EU/mL for Anti-CS or with titer ≥ 10 mIU/mL for Anti-HBsAg; 95% CI: 95% confidence interval; LL: Lower Limit, UL: Upper Limit; Pre: Pre-vaccination; PIII(M3): blood sampling taken 3 months after the first dose of vaccine; PIII(M14): blood sampling taken 14 months after the first dose of vaccine